CoChat
Sign Up
Cited by 472Diabetes Management and ResearchDiabetes Treatment and ManagementPatient Safety and Medication Errors

The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.

Hypoglycaemia in Type 2 diabetes

Open access
Amiel, S. A., Dixon, T., Mann, R., Jameson, K.·2008·Diabetic Medicine
DOI 10.1111/j.1464-5491.2007.02341.xPMC PMC2327221
Open this paper in CoChat — free accountOpen PDF

Abstract

The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in particular, those which raise insulin levels independently of blood glucose, such as sulphonylureas (SUs) and exogenous insulin. The risk of hypoglycaemia is increased in older patients, those with longer diabetes duration, lesser insulin reserve and perhaps in the drive for strict glycaemic control. Differing definitions, data collection methods, drug type/regimen and patient populations make comparing rates of hypoglycaemia difficult. It is clear that patients taking insulin have the highest rates of self‐reported severe hypoglycaemia (25% in patients who have been taking insulin for > 5 years). SUs are associated with significantly lower rates of severe hypoglycaemia. However, large numbers of patients take SUs in the UK, and it is estimated that each year > 5000 patients will experience a severe event caused by their SU therapy which will require emergency intervention. Hypoglycaemia has substantial clinical impact, in terms of mortality, morbidity and quality of life. The cost implications of severe episodes—both direct hospital costs and indirect costs—are considerable: it is estimated that each hospital admission for severe hypoglycaemia costs around £1000. Hypoglycaemia and fear of hypoglycaemia limit the ability of current diabetes medications to achieve and maintain optimal levels of glycaemic control. Newer therapies, which focus on the incretin axis, may carry a lower risk of hypoglycaemia. Their use, and more prudent use of older therapies with low risk of hypoglycaemia, may help patients achieve improved glucose control for longer, and reduce the risk of diabetic complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2007.02341.x

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The effect of duration of diabetes on the proportion of patients experiencing severe hypoglycaemic episodes. The open circles represent patients in the intensive arm in the United Kingdom Prospective Diabetes Study (UKPDS) and show an increase in the proportion of patients experiencing a severe hypoglycaemic event over time. In contrast the closed circles represent patients in the diet-only arm of UKPDS and do not show an increase [21]. Reprinted from The Lancet, 352: UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, 837–853, Copyright 1998, with permission from Elsevier.
FIGURE 1 The effect of duration of diabetes on the proportion of patients experiencing severe hypoglycaemic episodes. The open circles represent patients in the intensive arm in the United Kingdom Prospective Diabetes Study (UKPDS) and show an increase in the proportion of patients experiencing a severe hypoglycaemic event over time. In contrast the closed circles represent patients in the diet-only arm of UKPDS and do not show an increase [21]. Reprinted from The Lancet, 352: UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, 837–853, Copyright 1998, with permission from Elsevier.CC BY · PubMed Central
FIGURE 2 Proportion of patients with Type 2 and Type 1 diabetes of differing durations and receiving different regimens experiencing at least one severe hypoglycaemic attack during 9–12 months’ follow-up. All patients were receiving insulin except the group treated with sulphonylurea [35]. Reproduced from [35] with kind permission of Springer Science and Business Media.
FIGURE 2 Proportion of patients with Type 2 and Type 1 diabetes of differing durations and receiving different regimens experiencing at least one severe hypoglycaemic attack during 9–12 months’ follow-up. All patients were receiving insulin except the group treated with sulphonylurea [35]. Reproduced from [35] with kind permission of Springer Science and Business Media.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Research works printed but not linked: 3

  1. Canadian Diabetes Association, 2003, Hypoglycemia, Can J Diabetes, 27, S43
  2. 10.1210/jc.82.5.1458 · DOI
  3. Curtis L, 2006, Unit Costs of Health and Social Care

Cited by

Sorted by citations

Items 301–400 of 472

Related

See all

Metadata

Authors
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K.
Affiliations
  • King's College London (GB)
  • University of Sheffield (GB)
  • MSD (UK) Limited (United Kingdom) (GB)
Corresponding author
Amiel, S. A.
ORCID
Venue
Diabetic Medicine
Publisher
Wiley
Published
2008-02-27
Volume
25
Issue
3
Pages
245-254
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
DOI
10.1111/j.1464-5491.2007.02341.x
PMC
PMC2327221
OpenAlex
W2156888511
Cited by
472
References
77
Citations by year
2026: 4 · 2025: 7 · 2024: 10 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 15 · 2019: 22 · 2018: 34 · 2017: 17 · 2016: 29 · 2015: 33 · 2014: 46 · 2013: 55 · 2012: 46
FWCI
5.23
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetic Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
hypoglycemia, type 2 diabetes, sulfonylureas, insulin therapy, severe hypoglycemia, glycemic control, incretin-based therapy, hospital costs, diabetes complications
MeSH terms
Diabetes Mellitus, Type 2, Hospitalization, Humans, Hypoglycemia, Insulin, Risk Factors, Sulfonylurea Compounds, Antidiuretic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review